Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism

Merajoth, Abhijith Lalesh; Pillai, Pradeep Sadasivan; Iype, Thomas

doi:10.7860/jcdr/2016/16043.7886

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…L-dopa is administered orally, so its bioavailability depends on the degree of metabolic processing by intestinal and hepatic enzymes before it reaches the brain [ 258 ]. Thus, it is usually given in combination with an AADC inhibitor such as carbidopa in order to minimize its peripheral metabolism [ 259 ] and ensure that sufficient L-dopa will reach the brain. However, pharmacokinetics of L-dopa has been found to be highly variable between patients and its efficacy decreases over time of treatment, and sometimes it is even ineffective in some patients [ 260 ].…”

Section: Targeting the Gut–brain Axis In Pdmentioning

confidence: 99%

New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota

Lorente-Picón

Laguna

2021

Biomolecules

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, and for which no disease-modifying treatments exist. Neurodegeneration and neuropathology in different brain areas are manifested as both motor and non-motor symptoms in patients. Recent interest in the gut–brain axis has led to increasing research into the gut microbiota changes in PD patients and their impact on disease pathophysiology. As evidence is piling up on the effects of gut microbiota in disease development and progression, another front of action has opened up in relation to the potential usage of microbiota-based therapeutic strategies in treating gastrointestinal alterations and possibly also motor symptoms in PD. This review provides status on the different strategies that are in the front line (i.e., antibiotics; probiotics; prebiotics; synbiotics; dietary interventions; fecal microbiota transplantation, live biotherapeutic products), and discusses the opportunities and challenges the field of microbiome research in PD is facing.

show abstract

Section: Targeting the Gut–brain Axis In Pdmentioning

confidence: 99%

New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota

Lorente-Picón

Laguna

2021

Biomolecules

View full text Add to dashboard Cite

show abstract

“…The life quality of patients can be improved also by brain stimulation. Peripheral dopa‐decarboxylase inhibitors, such as carbidopa, can be administered in combination with levodopa to improve its absorption and passage through the central nervous system (carbidopa prevents levodopa from being transformed into dopamine before reaching the brain) 27 . However, as for AD, the progression of the disease can be slowed but never stopped really 28 .…”

Section: Neurodegenerationmentioning

confidence: 99%

Gold and silver nanoparticles in Alzheimer's and Parkinson's diagnostics and treatments

Scarpa

Cascione

Griego

et al. 2023

Ibrain

View full text Add to dashboard Cite

Neurodegenerative diseases (NDs) impose substantial medical and public health burdens on people worldwide and represent one of the major threats to human health. The prevalence of these age‐dependent disorders is dramatically increasing over time, a process intrinsically related to a constantly rising percentage of the elderly population in recent years. Among all the NDs, Alzheimer's and Parkinson's are considered the most debilitating as they cause memory and cognitive loss, as well as severely affecting basic physiological conditions such as the ability to move, speak, and breathe. There is an extreme need for new and more effective therapies to counteract these devastating diseases, as the available treatments are only able to slow down the pathogenic process without really stopping or resolving it. This review aims to elucidate the current nanotechnology‐based tools representing a future hope for NDs treatment. Noble metal nano‐systems, that is, gold and silver nanoparticles (NPs), have indeed unique physicochemical characteristics enabling them to deliver any pharmacological treatment in a more effective way within the central nervous system. This can potentially make NPs a new hope for reversing the actual therapeutic strategy based on slowing down an irreversible process into a more effective and permanent treatment.

show abstract

Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism

Cited by 2 publications

References 13 publications

New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota

New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota

Gold and silver nanoparticles in Alzheimer's and Parkinson's diagnostics and treatments

Contact Info

Product

Resources

About